Terms: = Prostate cancer AND MET, RCCP2, 4233, ENSG00000105976, P08581, HGFR, AUTS9 AND Treatment
1014 results:
1. A systematic review of combined surgery and brachytherapy approaches for children and young people with relapsed and refractory rhabdomyosarcoma (Local-REFoRMS).
Ballantyne E; Evans C; Shepherd L; Fulbright H; Wakeling S; Phillips B; Morgan JE
Pediatr Blood Cancer; 2024 Jun; 71(6):e30952. PubMed ID: 38566349
[TBL] [Abstract] [Full Text] [Related]
2. Compliance With NCCN Guidelines for Evaluation and treatment of Anemia Among Patients With Solid Tumors.
Hufnagel DH; Bos LM; Brown AJ; Prescott LS
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38489926
[TBL] [Abstract] [Full Text] [Related]
3. Demonstrating Bioequivalence for Two Dose Strengths of Niraparib and Abiraterone Acetate Dual-Action Tablets Versus Single Agents: Utility of Clinical Study Data Supplemented with Modeling and Simulation.
Yu A; Hazra A; Jiao JJ; Hellemans P; Mitselos A; Tian H; Ruixo JJP; Haddish-Berhane N; Ouellet D; Russu A
Clin Pharmacokinet; 2024 Apr; 63(4):511-527. PubMed ID: 38436924
[TBL] [Abstract] [Full Text] [Related]
4. Magnetic resonance guided adaptive post prostatectomy radiotherapy: Accumulated dose comparison of different workflows.
Hassan SP; de Leon J; Batumalai V; Moutrie Z; Hogan L; Ge Y; Stricker P; Jameson MG
J Appl Clin Med Phys; 2024 Apr; 25(4):e14253. PubMed ID: 38394627
[TBL] [Abstract] [Full Text] [Related]
5. Development of depression in patients using androgen deprivation therapy: A systemic review and meta-analysis.
Qazi SU; Altaf Z; Zafar M; Tariq MA; Khalid A; Kaleem A; Saad E; Qazi S
Prostate; 2024 May; 84(6):525-538. PubMed ID: 38372065
[TBL] [Abstract] [Full Text] [Related]
6. 1,3-Disubstituted-1,2,4-triazin-6-ones with potent activity against androgen receptor-dependent prostate cancer cells.
Zhao S; Ali AS; Liu X; Yu Z; Kong X; Zhang Y; Paul Savage G; Xu Y; Lin B; Wu D; Francis CL
Bioorg Med Chem; 2024 Mar; 101():117634. PubMed ID: 38359754
[TBL] [Abstract] [Full Text] [Related]
7. Comparing the use of aggressive end-of life care among frail and non-frail patients with cancer using a claims-based frailty index.
Sachdev R; Shearn-Nance G; Vu L; Bensken WP; Douglas SL; Koroukian SM; Rose J
J Geriatr Oncol; 2024 Mar; 15(2):101706. PubMed ID: 38320468
[TBL] [Abstract] [Full Text] [Related]
8. Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis.
Xiong X; Zhang S; Zheng W; Liao X; Yang J; Xu H; Hu S; Wei Q; Yang L
Crit Rev Oncol Hematol; 2024 Apr; 196():104286. PubMed ID: 38316286
[TBL] [Abstract] [Full Text] [Related]
9. Magnetic resonance imaging-ultrasound fusion guided focal cryoablation for men with intermediate-risk prostate cancer.
Sidana A; Tayebi S; Blank F; Lama DJ; Meyer M; Saeed Y; Tobler J; Hsu WW; Verma S
Urol Oncol; 2024 May; 42(5):158.e1-158.e10. PubMed ID: 38245407
[TBL] [Abstract] [Full Text] [Related]
10. Simulation and pre-planning omitted radiotherapy (SPORT): a feasibility study for prostate cancer.
Zhuang T; Parsons D; Desai N; Gibbard G; Keilty D; Lin MH; Cai B; Nguyen D; Chiu T; Godley A; Pompos A; Jiang S
Biomed Phys Eng Express; 2024 Feb; 10(2):. PubMed ID: 38241733
[TBL] [Abstract] [Full Text] [Related]
11. Harnessing function of EMT in cancer drug resistance: a metastasis regulator determines chemotherapy response.
Ebrahimi N; Manavi MS; Faghihkhorasani F; Fakhr SS; Baei FJ; Khorasani FF; Zare MM; Far NP; Rezaei-Tazangi F; Ren J; Reiter RJ; Nabavi N; Aref AR; Chen C; Ertas YN; Lu Q
Cancer Metastasis Rev; 2024 Mar; 43(1):457-479. PubMed ID: 38227149
[TBL] [Abstract] [Full Text] [Related]
12. Incidental carcinoma of the prostate in cystoprostatectomy specimens - is it always a toothless lion?
Dema V; Croitor A; Floruncuţ A; Dema S; Bardan TR; Tăban SM; Barna RA; Natarâş BR; Cumpănaş AA
Rom J Morphol Embryol; 2023; 64(4):501-507. PubMed ID: 38184830
[TBL] [Abstract] [Full Text] [Related]
13. Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With metastatic Hormone-Sensitive prostate cancer.
Halabi S; Roy A; Rydzewska L; Guo S; Godolphin P; Hussain M; Tangen C; Thompson I; Xie W; Carducci MA; Smith MR; Morris MJ; Gravis G; Dearnaley DP; Verhagen P; Goto T; James N; Buyse ME; Tierney JF; Sweeney C;
J Clin Oncol; 2024 Mar; 42(9):1044-1054. PubMed ID: 38181323
[TBL] [Abstract] [Full Text] [Related]
14. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Markowski MC; Taplin ME; Aggarwal R; Sena LA; Wang H; Qi H; Lalji A; Sinibaldi V; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Sanin DE; Yegnasubramanian S; Gomes-Alexandre C; Ozbek B; Jones T; De Marzo AM; Denmeade SR; Antonarakis ES
Nat Commun; 2024 Jan; 15(1):14. PubMed ID: 38167882
[TBL] [Abstract] [Full Text] [Related]
15. ARCHERY: a prospective observational study of artificial intelligence-based radiotherapy treatment planning for cervical, head and neck and prostate cancer - study protocol.
Aggarwal A; Court LE; Hoskin P; Jacques I; Kroiss M; Laskar S; Lievens Y; Mallick I; Abdul Malik R; Miles E; Mohamad I; Murphy C; Nankivell M; Parkes J; Parmar M; Roach C; Simonds H; Torode J; Vanderstraeten B; Langley R
BMJ Open; 2023 Dec; 13(12):e077253. PubMed ID: 38149419
[TBL] [Abstract] [Full Text] [Related]
16. Exploring Men's Experiences with Follow-Up Care following Primary treatment for prostate cancer in Atlantic Canada: A Qualitative Study.
Urquhart R; Scruton S; Radford S; Kendell C; Hirsch E
Curr Oncol; 2023 Nov; 30(12):10111-10123. PubMed ID: 38132369
[TBL] [Abstract] [Full Text] [Related]
17. Do all prostate cancer patients want, and experience shared decision making prior to curative treatment?
Otrebski Nilsson M; Aas K; Myklebust TÅ; Gjelsvik YM; Haug ES; Fosså SD; Johannesen TB
Scand J Urol; 2023 Dec; 58():133-140. PubMed ID: 38116675
[TBL] [Abstract] [Full Text] [Related]
18. Novel signatures of prostate cancer progression and therapeutic resistance.
Wang J; Ben-David R; Mehrazin R; Yang W; Tewari AK; Kyprianou N
Expert Opin Ther Targets; 2023; 27(12):1195-1206. PubMed ID: 38108262
[TBL] [Abstract] [Full Text] [Related]
19. Induction of double-strand breaks with the non-steroidal androgen receptor ligand flutamide in patients on androgen suppression: a study protocol for a randomized, double-blind prospective trial.
Lee E; Coulter J; Mishra A; Caramella-Pereira F; Demarzo A; Rudek M; Hu C; Han M; DeWeese TL; Yegnasubramanian S; Song DY
Trials; 2023 Dec; 24(1):809. PubMed ID: 38104131
[TBL] [Abstract] [Full Text] [Related]
20. Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.
McNeel DG; Emamekhoo H; Eickhoff JC; Kyriakopoulos CE; Wargowski E; Tonelli TP; Johnson LE; Liu G
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38101860
[TBL] [Abstract] [Full Text] [Related]
[Next]
